Authority library
Dog longevity evidence guides
A deliberately small collection of source-checked answers. Each guide separates what is known, sponsor-reported, unproven, and time-sensitive.
LOY-002 for dogs: eligibility, FDA status, mechanism, and evidence
A neutral, source-checked LOY-002 profile covering intended dogs, development status, safety milestones, mechanism claims, and unanswered questions.
LOY-001 vs. LOY-003: large-dog longevity programs compared
Compare LOY-001 and LOY-003 by intended age, weight, dosage form, biological target, and regulatory evidence without confusing development claims with approval.
Rapamycin for dogs: what the TRIAD longevity study can—and cannot—show
Understand canine rapamycin research, the Dog Aging Project TRIAD study, evidence limits, safety questions, and why a trial is not a home-treatment protocol.
FDA conditional approval for dog drugs: what it actually means
Plain-English FDA conditional approval guide for animal drugs: safety, reasonable expectation of effectiveness, full approval, renewals, and label limits.
Dog longevity pill cost: verified price versus speculation
What is—and is not—known about LOY-002 price, veterinary costs, monitoring, insurance, and total cost of care before an approved label exists.
Dog longevity pill safety: evidence, unknowns, and veterinarian questions
A careful guide to LOY-002 safety milestones, missing public data, adverse-event interpretation, interactions, monitoring, and owner questions.
Dog longevity clinical trials: LOY-002 STAY, rapamycin TRIAD, and eligibility
Compare major canine longevity studies, learn what enrollment means, and verify trial eligibility, placebo design, costs, locations, and informed consent.
Dog longevity supplements vs. drugs: evidence and regulation compared
Compare canine longevity supplements with FDA-approved or conditionally approved animal drugs by claims, evidence, manufacturing, labeling, and veterinary oversight.